Literature DB >> 20362457

Slower progression of atherosclerosis in vein grafts harvested with 'no touch' technique compared with conventional harvesting technique in coronary artery bypass grafting: an angiographic and intravascular ultrasound study.

Benny L Johansson1, Domingos S R Souza, Lennart Bodin, Derek Filbey, Andrzej Loesch, Håkan Geijer, Leif Bojö.   

Abstract

OBJECTIVES: In a long-term randomised coronary artery bypass grafting (CABG) study, the patency rate using a new 'no touch' (NT) vein-graft preparation technique was superior to the conventional (C) technique. This cineangiographic and intravascular ultrasound (IVUS) substudy examined possible mechanisms.
METHODS: A total of 45 patients (118 grafts) in the NT group and 46 patients (112 grafts) in the C group had patent grafts at short-term follow-up after 18 months. Thirty-seven patients (91 grafts) in the NT group and 37 patients (77 grafts) in the C group had patent grafts at long-term follow-up after 8.5 years, and were evaluated on a scale from 0 (normal) to 2 (significant stenosis) by cineangiogram. IVUS was performed in 15 NT grafts and 14 C grafts in the short-term follow-up, and 27 NT grafts and 26 C grafts in the long-term follow-up, in grafts considered normal by the cineangiogram. The grafts were evaluated with respect to lumen volume, intimal thickness, incidence of plaque and plaque components.
RESULTS: In the short-term follow-up, the cineangiogram showed more normal grafts (89.0% in the NT group compared with 75.0% in the C group), and the number of grafts with stenosis was 11.0% in the NT group compared with 25.0% in the C group (p=0.006). IVUS showed less mean intimal thickness (0.43 (0.07)mm vs 0.52 (0.08)mm; p=0.03), less grafts with considerable intimal hyperplasia (≥ 0.9 mm; 20% vs 78.6%; p=0.011) and fewer patients with considerable hyperplasia (≥ 0.9 mm; 25% vs 100%; p=0.007). In the long-term follow-up, the cineangiogram showed more normal grafts, with 91.2% in the NT group compared with 83.1% in the C group; there were fewer grafts with significant stenosis, with 7.7% in the NT group compared with 15.6% in the C group (p=0.14). IVUS showed fewer grafts containing multiple plaques (14.8% vs 50%; p=0.008), less advanced plaque with lipid (11.8% vs 63.9%; p=0.0004) and less maximal plaque thickness (1.04 (0.23)mm vs 1.32 (0.25)mm; p=0.02) in the NT group compared with the C group.
CONCLUSION: The superior long-term patency rate using the NT vein-graft technique at CABG could be explained by a significantly slower progression of atherosclerosis.
Copyright © 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2010        PMID: 20362457     DOI: 10.1016/j.ejcts.2010.02.007

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  20 in total

1.  No-touch vein grafts and the destiny of venous revascularization in coronary artery bypass grafting-a 25th anniversary perspective.

Authors:  Ninos Samano; Michael Dashwood; Domingos Souza
Journal:  Ann Cardiothorac Surg       Date:  2018-09

2.  Does No-Touch Technique Better than Conventional or Intermediate Saphenous Vein Harvest Techniques for Coronary Artery Bypass Graft Surgery: a Systematic Review and Meta-analysis.

Authors:  Abdelrahman Elshafay; Ahmed Hesham Bendary; Huan Thanh Vuong; Ahmed Reda Ahmed; Mohamed Ashraf Mokhtar; Ali Lotfy Soliman; Nguyen Lam Vuong; Israa Atia El Bestawi; Nirmeen Atef Abdallah; Vi Tuong Vu; Kenji Hirayama; Nguyen Tien Huy
Journal:  J Cardiovasc Transl Res       Date:  2018-10-12       Impact factor: 4.132

3.  Surgical skin markers impair human saphenous vein graft smooth muscle and endothelial function.

Authors:  Susan Eagle; Colleen M Brophy; Padmini Komalavilas; Kyle Hocking; Gowthami Putumbaka; Michael Osgood; Kevin Sexton; Marzia Leacche; Joyce Cheung-Flynn
Journal:  Am Surg       Date:  2011-07       Impact factor: 0.688

4.  Brilliant blue FCF as an alternative dye for saphenous vein graft marking: effect on conduit function.

Authors:  Igor V Voskresensky; Eric S Wise; Kyle M Hocking; Fan Dong Li; Michael J Osgood; Padmini Komalavilas; Colleen Brophy; Joyce Cheung-Flynn
Journal:  JAMA Surg       Date:  2014-11       Impact factor: 14.766

5.  CD68 expression in aortocoronary saphenous vein bypass grafts.

Authors:  Agnieszka Malinska; Bartlomiej Perek; Piotr Buczkowski; Katarzyna Kowalska; Danuta Ostalska-Nowicka; Wojciech Witkiewicz; Michal Nowicki
Journal:  Histochem Cell Biol       Date:  2012-12-30       Impact factor: 4.304

Review 6.  Strategies for the coronary surgeon to remain "competitive and co-operative" in the PCI era.

Authors:  George Jose Valooran; Shiv Kumar Nair; Krishnan Chandrasekharan
Journal:  Indian Heart J       Date:  2015-07-08

Review 7.  Saphenous vein grafts in contemporary coronary artery bypass graft surgery.

Authors:  Etem Caliskan; Domingos Ramos de Souza; Andreas Böning; Oliver J Liakopoulos; Yeong-Hoon Choi; John Pepper; C Michael Gibson; Louis P Perrault; Randall K Wolf; Ki-Bong Kim; Maximilian Y Emmert
Journal:  Nat Rev Cardiol       Date:  2019-08-27       Impact factor: 32.419

Review 8.  Coronary Artery Bypass: Review of Surgical Techniques and Impact on Long-Term Revascularization Outcomes.

Authors:  Brian McNichols; John R Spratt; Jerin George; Scott Rizzi; Eddie W Manning; Ki Park
Journal:  Cardiol Ther       Date:  2021-01-30

9.  Comparison of the one-year patency rates of radiocephalic arteriovenous fistulas created using no-touch versus conventional technique.

Authors:  İsmail Oral Hastaoğlu; Hamdi Toköz; Ayça Özgen; Fuat Bilgen
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2019-01-01       Impact factor: 0.332

10.  Perivascular Adipose Tissue Is a Major Source of Nitric Oxide in Saphenous Vein Grafts Harvested via the No-Touch Technique.

Authors:  Toshiro Saito; Hiroshi Kurazumi; Ryo Suzuki; Kazumasa Matsunaga; Sarii Tsubone; Bochao Lv; Sei Kobayashi; Takashi Nagase; Takahiro Mizoguchi; Makoto Samura; Kotaro Suehiro; Takasuke Harada; Noriyasu Morikage; Akihito Mikamo; Kimikazu Hamano
Journal:  J Am Heart Assoc       Date:  2022-01-19       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.